Exagen Diagnostics Names Dr. Thomas Williams Chief Science Officer and Vice President, Research and Development

Mar 06, 2006, 00:00 ET from Exagen Diagnostics, Inc.

    ALBUQUERQUE, N.M., March 6 /PRNewswire/ -- Exagen Diagnostics, Inc., which
 develops and commercializes genomic marker-based in vitro diagnostic (IVD)
 kits for prognosis and prediction of treatment response, today announced that
 Dr. Thomas Williams has been named chief science officer and vice president,
 research and development. Williams will spearhead the company's scientific
 strategy, including genomic marker validation, product development functions
 and collaborative relationships with key customers.
     "Exagen has benefited from Tom's expertise since the company's inception,"
 said Exagen CEO James McClintic. "His extensive record of accomplishment in
 clinical molecular diagnostics, molecular genetics research and clinical
 research makes him the ideal person to direct our scientific efforts as we
 bring our products to market."
     Prior to joining Exagen as a full-time employee, Williams served as the
 company's special advisor for molecular pathology. Additionally, he was vice
 chairman, department of pathology, at the University of New Mexico (UNM)
 School of Medicine and director of the Genetics and Cytometry Division at
 TriCore Reference Laboratories, a regional medical laboratory affiliated with
 UNM Health Sciences Center and Presbyterian Healthcare Services. Williams will
 continue with UNM as part-time professor of pathology.
     About Exagen Diagnostics, Inc.
     An emerging leader in the development of prognostic and predictive in
 vitro diagnostic (IVD) kits, Exagen is uniquely able to discover, validate and
 productize small sets of genomic markers for use in oncology, infectious
 disease and other indications. The company's first tests predict the risk of
 breast cancer recurrence, so that women with a low or elevated risk of
 recurrence can be identified with high accuracy. Exagen plans to submit its
 tests to the Food and Drug Administration for clearance later this year, and
 will be the first to market a set of genomic markers for breast cancer
 prognosis using a fluorescent in situ hybridization (FISH) test. For more
 information, visit http://www.exagen.com.

SOURCE Exagen Diagnostics, Inc.